Followers | 19 |
Posts | 2773 |
Boards Moderated | 0 |
Alias Born | 10/12/2006 |
Wednesday, March 30, 2022 5:58:10 AM
Recent MEIP News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2024 08:05:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/19/2024 09:20:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 09:05:07 PM
- MEI Pharma Reports Fiscal Year End 2024 Cash Position • Business Wire • 09/19/2024 08:01:00 PM
- MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives • Business Wire • 08/12/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:05:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 09:25:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 08:06:33 PM
- MEI Pharma to Consider Strategic Alternatives • Business Wire • 07/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 05:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:02:15 PM
- MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 05/09/2024 08:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:00:47 PM
- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 • Business Wire • 04/11/2024 12:02:00 PM
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients • Business Wire • 04/11/2024 12:00:00 PM
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum • Business Wire • 04/10/2024 12:00:00 PM
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia • Business Wire • 03/26/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/29/2024 05:15:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:00:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 10:33:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 10:05:14 PM
- MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 02/13/2024 10:05:00 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM